Growing evidence shows that bacteria within the tumor microenvironment can contribute to immune suppression, therapy resistance, and disease progression.
Our lead program focuses on Fusobacterium nucleatum, a bacterium strongly associated with colorectal cancer biology and poor clinical outcome. We are developing targeted immunotherapies aimed at restoring treatment sensitivity and anti-tumor immunity.
Our lead program targets Fusobacterium nucleatum, a tumor-associated bacterium linked to colorectal cancer progression and reduced treatment sensitivity.
Currently in preclinical development, the program is designed to reduce the impact of tumor-associated bacteria and help restore anti-tumor immune responses.
Bactheravax was selected as UNIIQ's 100th investment, supporting development of its lead immunotherapy program targeting tumor-associated bacteria in cancer.
The investment supports continued preclinical and translational development of the company's lead program.
Co-founder & CEO
Ivo Ploemen is a biotech entrepreneur with a background in medical microbiology and vaccine development.
He focuses on translating biological insights into scalable therapeutic strategies and building companies around high-impact scientific innovation, building on extensive experience in business development and strategic partnerships.
Co-founder & CSO
Dinja Oosterhoff is a translational immunology expert and biotech entrepreneur with deep expertise in oncology and immunotherapy. She leads the scientific strategy and development of the platform, translating biological insights into therapeutic approaches and bridging immune biology with clinical application to improve patient outcomes.
